APA (7th ed.) Citation

A, C., KM, C., G, P., D, D., & C, C. (2025). Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes. Frontiers in endocrinology, 16, 1531295. https://doi.org/10.3389/fendo.2025.1531295

Chicago Style (17th ed.) Citation

A, Colletta, Cooper KM, Placentino G, Devuni D, and Colletta C. "Sodium-glucose Cotransporter-2 Inhibitor Therapy Improves Renal and Hepatic Function in Patients with Cirrhosis Secondary to Metabolic Dysfunction Associated Steatotic Liver Disease and Type 2 Diabetes." Frontiers in Endocrinology 16 (2025): 1531295. https://doi.org/10.3389/fendo.2025.1531295.

MLA (9th ed.) Citation

A, Colletta, et al. "Sodium-glucose Cotransporter-2 Inhibitor Therapy Improves Renal and Hepatic Function in Patients with Cirrhosis Secondary to Metabolic Dysfunction Associated Steatotic Liver Disease and Type 2 Diabetes." Frontiers in Endocrinology, vol. 16, 2025, p. 1531295, https://doi.org/10.3389/fendo.2025.1531295.